BRPI0413342A - composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto - Google Patents

composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto

Info

Publication number
BRPI0413342A
BRPI0413342A BRPI0413342-0A BRPI0413342A BRPI0413342A BR PI0413342 A BRPI0413342 A BR PI0413342A BR PI0413342 A BRPI0413342 A BR PI0413342A BR PI0413342 A BRPI0413342 A BR PI0413342A
Authority
BR
Brazil
Prior art keywords
mammals
treat
compound
obsessive
pharmaceutical composition
Prior art date
Application number
BRPI0413342-0A
Other languages
English (en)
Inventor
Christopher Stanley Galka
Michael John Rodriguez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0413342A publication Critical patent/BRPI0413342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA AUMENTAR SELETIVAMENTE A ATIVAçãO DO RECEPTOR DE 5HT~ 2C~ EM MAMìFEROS, PARA TRATAR OBESIDADE EM MAMìFEROS, PARA TRATAR DISTúRBIO OBSESSIVO/ COMPULSIVO EM MAMìFEROS PARA TRATAR DEPRESSãO EM MAMìFEROS E PARA TRATAR ANSIEDADE EM MAMìFEROS, E, USO DE UM COMPOSTO". A presente invenção fornece um 7-cloro-6-(2,2,2-trifluoroetilamino)-2,3,4,5-tetraidro- 1H-benzo¢d!azepina da Fórmula (I): ou um sal deste farmaceuticamente aceitável e seu uso como um agonista de 5-HT~ 2C~ seletivo para o tratamento de distúrbios associados com 5-HT~ 2C~ incluindo obesidade, distúrbio obsessivo/compulsivo, ansiedade e depressão.
BRPI0413342-0A 2003-08-11 2004-07-30 composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto BRPI0413342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49420803P 2003-08-11 2003-08-11
PCT/US2004/022299 WO2005019180A1 (en) 2003-08-11 2004-07-30 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST

Publications (1)

Publication Number Publication Date
BRPI0413342A true BRPI0413342A (pt) 2006-10-10

Family

ID=34215860

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413342-0A BRPI0413342A (pt) 2003-08-11 2004-07-30 composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto

Country Status (11)

Country Link
US (1) US20060264418A1 (pt)
EP (1) EP1656352A1 (pt)
JP (1) JP2007502272A (pt)
CN (1) CN1832926A (pt)
AR (1) AR045229A1 (pt)
AU (1) AU2004267027A1 (pt)
BR (1) BRPI0413342A (pt)
CA (1) CA2532020A1 (pt)
MX (1) MXPA06001647A (pt)
TW (1) TW200510324A (pt)
WO (1) WO2005019180A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
CA2619450C (en) * 2005-09-01 2013-10-22 Eli Lilly And Company 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
AU2006287202B2 (en) 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
CN101253153A (zh) 2005-09-01 2008-08-27 伊莱利利公司 作为5－HT<sub>2c</sub>受体激动剂的6－取代的2,3,4,5－四氢－1H－苯并[d]氮杂䓬
ATE438627T1 (de) 2005-09-01 2009-08-15 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2288585A1 (en) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
AU2011296015B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
AU2011296027A1 (en) * 2010-09-01 2013-04-04 Arena Pharmaceuticals, Inc. Fast-dissolve dosage forms of 5-HT2C agonists
JP2013536859A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの非吸湿性塩
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
JP2015534563A (ja) 2012-10-09 2015-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 体重管理の方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498122A (de) * 1968-02-09 1970-10-31 Geigy Ag J R Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
FR2358151A1 (fr) * 1976-03-31 1978-02-10 Roussel Uclaf Nouvelles benzazepines et leurs sels, procede de preparation et application a titre de medicaments
WO1993000094A2 (en) * 1991-06-21 1993-01-07 Smithkline Beecham Plc Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
WO2002074746A1 (en) * 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
EP1451176A2 (en) * 2001-11-28 2004-09-01 PHARMACIA &amp; UPJOHN COMPANY Benzazepine derivatives and their use as 5-ht ligands
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
GB0212399D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20060264418A1 (en) 2006-11-23
WO2005019180A1 (en) 2005-03-03
EP1656352A1 (en) 2006-05-17
CN1832926A (zh) 2006-09-13
JP2007502272A (ja) 2007-02-08
TW200510324A (en) 2005-03-16
AU2004267027A1 (en) 2005-03-03
CA2532020A1 (en) 2005-03-03
MXPA06001647A (es) 2006-04-28
AR045229A1 (es) 2005-10-19

Similar Documents

Publication Publication Date Title
BRPI0413342A (pt) composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto
NO20064277L (no) 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister
DE60018274D1 (de) Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden
MXPA05013364A (es) Procedimiento para preparar 3-benzazepinas.
BRPI0309303B8 (pt) compostos moduladores de receptores de 5ht2c, composição farmacêutica, e uso dos referidos compostos
BR9916326A (pt) Derivados de 2,3,4,4a-tetrahidro-1h-pirazino(1,2-a)quinoxalin-5-(6h) ona sendo agonistas de 5ht2c
DE60231202D1 (de) Kondensierte heterozyklische verbindungen
BR0009539A (pt) composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
ATE247639T1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
AR031200A1 (es) Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
BR0103210A (pt) Derivados de azabicicloalcano e suas utilizações terapêuticas
BR0013664A (pt) Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa
ATE438627T1 (de) 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
MX2008002180A (es) 2,3,4,5-tetrahidro-1h-benzo[d]azepinas 6-sustituidas como agonistas de receptor 5-ht2c.
DK1381614T3 (da) Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2,3-f]quinoxalin
DK1381615T3 (da) Antidepressive indoltetrahydropyridinderivater af 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indol
BRPI0410127A (pt) derivados de pirimidina substituìdos
BR0113696A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, e, métodos para tratar de uma doença ou distúrbio associados com o agonismo patogênico, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, para alterar a atividade transdutora de sinal dos receptores de gabaa e para preparar um composto
TNSN05315A1 (en) Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
BRPI0412268A (pt) compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a
BRPI0409180A (pt) compostos de pirrol[1,2-b]piridazina e seus usos como antagonistas do receptor cfr-1
BRPI0511419A (pt) derivado de lactama de pirazinilmetila
DOP2004000972A (es) 6-(2,2,2-trifluoroetilamino)-7-cloro-2,3,4,5-tetrahidro 1h-benzo[d] azepina como agonista del receptor 5-ht2c

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]